Meeting
2015 ASCO Annual Meeting
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
Authors
Ashley Ghiaseddin
Duke University Medical Center, Durham, NC
Ashley Ghiaseddin , David A. Reardon , Woody Massey , Alexandra Mannerino , Eric S. Lipp , James E. Herndon II, Frances McSherry , Annick Desjardins , Dina M Randazzo , Gordana Vlahovic , Henry S. Friedman , Katherine B Peters
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01738646
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2034)
DOI
10.1200/jco.2015.33.15_suppl.2034
Abstract #
2034
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
First Author: Manmeet Singh Ahluwalia
Poster
2020 ASCO Virtual Scientific Program
Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.
First Author: Jaleh Fallah
Poster
2015 ASCO Annual Meeting
Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102).
First Author: Vinay K. Puduvalli
Poster
2012 ASCO Annual Meeting
Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.
First Author: Katherine B. Peters